Clinical stage biopharmaceutical company Carisma Therapeutics Inc on Tuesday announced an expansion of its in vivo CAR-M collaboration with Moderna Inc (Nasdaq:MRNA) to include the development of two therapies for autoimmune diseases.
Building on their successful pre-clinical work in oncology, the companies will leverage their respective technologies to develop novel in vivo macrophage engineering approaches for two nominated autoimmune disease targets.
Carisma will receive research funding and milestone payments, as well as royalties on any commercialised products.
Sareum Holdings secures patent allowance for SDC-1801 in China
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval